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INTRODUCTION:
 Even though severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) primarily 
affects the respiratory system, the nervous system 
is not spared either. SARS-CoV-2 has been isolated 
from the brain, olfactory bulb and cerebrospinal 
fluid. During the SARS (SARS-CoV-1) outbreak in 
2002 to 2003, neurons had been found to be highly 
susceptible for infection and the virus could cause 
extensive neuronal damage. Similar to SARS-CoV-1, 
SARS-CoV-2 exploits the angiotensin-converting 
enzyme 2 (ACE-2) receptor to gain entry and infect 
both glial and neuronal cells which express ACE-2 
receptors.[1] SARS-CoV-2 affects the central as well 
as peripheral nervous system presenting with diverse 
manifestations like myelitis, cerebrovascular events 
(CVE) and encephalitis to mention a few.[2,3] In-
depth understanding of neurotropic potential of this 
virus will be helpful to individualize the treatment 
protocol from a neurological perspective.
REVIEW:
 The first report of the viral infection attracted 
attention in late December 2019 in Wuhan, the capital 
of Hubei, which quickly surged to potential of global 
threat and rapidly succeeded from China to Europe 
and then to the United States of America in a matter 
of weeks was taxonomically designated as SARS-
CoV-2 and diseases named as corona virus disease 
(COVID-19). COVID-19 was declared a pandemic 
on the March 11, 2020 by WHO.[4] Currently, 
SARS-CoV-2 has affected almost every country of 
the world with confirmed cases of 38,22,382 tolling 
2,63,658 death. In Nepal, as of May 10, 2020 there 
were 109 confirmed cases with zero mortality.[5]
VIRUS:
 SARS-CoV-2 is a single-strand RNA (ss-
RNA) corona virus similar to SARS like coronavirus 
that had previously been reported in bats in China. 
The RNA genome of SARS-CoV-2 is enclosed by 
spike (S), envelop (E) and membrane (M) protein. 
Spike protein projecting from the virus membrane is 
the key structure for the infectivity and pathogenicity 
of this virus into host. The spike protein enables the 
attachment of the virion to the cell membrane by 
interacting with the host ACE-2 receptor.[6] It has 
been found that the spike protein of SARS-CoV-2 has 
10-20 folds increased affinity to the ACE-2 receptor 
than SARS-CoV-1, making it highly contagious and 
infectious.[7,8]
MECHANISM OF NEURO INVASION:
 The mechanism of action for SARS-CoV-2 
neurological invasion is not yet specified. Capillary 
endothelium expresses ACE-2 receptors which is 
the vulnerable site for the access of the virus into 
the cerebral microcirculation. The lesion in the 
endothelial lining as a result of subsequent budding 
of the viral particle favors viral access to the brain. 
Once access into the cerebral environment, it 
interacts with the neuronal ACE-2 receptors and 
could initiate viral multiplication and neuronal 
damage has been seen in SARS-CoV in past and 
proposed for SARS-CoV-2 which need approval.
[9] Although, low expression of ACE-2 in glia 
and cerebral neurons is well documented, the 
specific site of entry of SARS-CoV-2 is not clearly 
identified.[10] One of the proposed routes of access 
of virus to the brain is via the cribriform plate close 
to the olfactory bulb. Other postulations are trans-
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synaptic viral transfer after initial peripheral nerve 
invasion. Direct invasion, blood circulation pathway, 
neuronal pathway, hypoxia injury, immune injury/
cytokine storm syndromes have also been proposed. 
[11,12,13,14]
MANIFESTATION OF NEUROLOGICAL 
INVOLVEMENT:
 Covid-19 is a highly contagious disease 
transmitted from droplets, aerosols and contact 
to nasal or ocular surfaces. The incubation period 
is generally 3-14 days but an extended period 
up to 24 days has been reported. Neurological 
symptoms vary with the level of nervous system 
involved. Involvement of central nervous system 
(CNS) manifests as dizziness, headache, impaired 
consciousness, acute cerebrovascular diseases, 
ataxia or seizure while peripheral nervous system 
(PNS) involvement manifests as taste impairment, 
anosmia, visual impairment or neuralgia. 
 Increased severity of COVID-19 increases 
the risk of neural involvement and complications.[15] 
Spectrum of complication of COVID-19 includes 
viral meningitis, encephalitis, post infectious acute 
disseminated encephalitis, post infectious brainstem 
encephalitis, Guillain Barre syndrome (GBS), acute 
necrotizing hemorrhagic encephalopathy.[2] ACE-2 
at the level of blood brain barrier may jeopardize the 
protective barrier giving way to viral encephalitis 
while spinal cord membrane expressing ACE-2 
receptor in a spinal vein may predispose to myelitis 
like feature. Systemic homeostasis dysregulation 
caused by pulmonary, renal, cardiac and circulatory 
damage in COVID-19 can result in secondary 
cerebral damage. However, a dominant cerebral 
involvement alone with the potential of causing 
cerebral edema in COVID-19 can take heavy toll 
before systemic dysregulation ensues.[8]
 Cerebrovascular events (CVE) including 
hemorrhagic or ischemic stroke or cerebral venous 
sinus thrombosis could be a presenting feature 
of COVID-19. In a study done by Filatov A et al., 
among 221 patients, 5.88% (13 patients) had CVE of 
which majority (11 patients) of them presented with 
acute ischemic stroke (4.9%) while 0.45% patients 
presented with hemorrhagic stroke.[3]
 In a retrospective study done by Mao L et al., 
in Wuhan, China among 214 patients hospitalized 
with laboratory confirmed diagnosis of SARS-
CoV-2 infection. Seventy-eight (36.4%) patients had 
neurologic manifestations. More severe patients were 
likely to have neurologic symptoms (40 [45.5%] vs 
38 [30.2%]), such as acute cerebrovascular diseases 
(5 [5.7%] vs 1 [0.8%]), impaired consciousness (13 
[14.8%] vs 3 [2.4%]. [10] There can be multiple 
reasons for a patient with COVID-19 to present 
with impaired consciousness which includes viral 
encephalitis, metabolic perturbation, infectious toxic 
encephalopathy, seizure with post ictal confusion 
and stroke.[15]
Seizure in COVID-19 patients has minimal incidences 
as observed by Mao et al.[15] Association of seizure 
in COVID-19 can be multifaceted. Proposed 
mechanism could be due to direct viral invasion 
of CNS, severe hypoxia induced, metabolic, septic 
encephalopathy, gliosis due to encephalopathy or 
due to fever.[16]
 GBS was recorded infrequently in different 
studies worldwide. In a very recent study done by 
Zhao et al., five cases of GBS diagnosed among 
COVID-19 patients, three presented as axonal 
variant while two cases presented as demyelinating 
variants.[17] Rapid deteriorating respiratory function 
of COVID-19 patients could be due to bulbar 
involvement by GBS and need to be accurately 
sought. On the basis of this observational series 
involving five patients, it is not possible to determine 
whether severe deficits and axonal involvement are 
typical features of COVID-19 associated GBS. 
CONCLUSION:
 SARS-CoV-2 can take a severe toll on the 
respiratory system. However, virus bears potential 
to infect the nervous system as well. Neural access 
via hematogenous route or cribriform plate ensues 
damage of either the central or the peripheral nervous 
system. Subtle neurological manifestation must be 
considered as a presenting feature of COVID-19 to 
early detect and treat this evil.
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